Home Articles Sputnik V shows strong safety profile with no hospitalisation cases among elderly:...
KEY STORY
-
The Russian Direct Investment Fund (RDIF), an investor of the Russian COVID-19 vaccine Sputnik V, announced on Sunday that the vaccine demonstrated a higher or equal tolerability profile in people above the age of 60 years, during the inoculation campaign in San-Marino.
-
As per an official release, Sputnik V also showed strong safety with no hospitalisation cases and tolerability among the elderly in the country.
-
The study was conducted among people in San Marino who received one or two doses of Sputnik V from March 4 to April 8. The results of the study were published in EClinicalMedicine, an open-access clinical journal published by The Lancet.
-
A descriptive analysis was later conducted to quantify the incidence of adverse events following immunisation on both occasions.
-
“Our results, albeit preliminary, suggest that Sputnik V has a high tolerability profile in the population aged ≥60 years in terms of short-term AEFIs. This preliminary analysis suggests a higher or equal tolerability profile of the Sputnik V vaccine in the 60+ age group, after both doses, as compared with other widely adopted Covid-19 vaccines,” said the statement.
-
“Our results also align with the findings of phase 1 and 2 previously conducted studies, then confirmed by phase 3 of the vaccine trial, in terms of overall safety and tolerability. No hospitalisations or deaths were reported. Nearly all reported AEFIs were mild or moderate and/or lasted less than 2 days,” it added.
-
Sputnik V is among the three COVID-19 vaccines currently being used in India for the nationwide vaccination drive. It was granted an emergency use authorisation in the country in April this year after Covaxin and Covishield.